Fate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference
Fate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference
SAN DIEGO, April 03, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the "Company" or "Fate Therapeutics") (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that the Company will present at the 23rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10, 2024 at 2:15 PM ET.
聖地亞哥，2024年4月3日（GLOBE NEWSWIRE）——致力於爲癌症和自身免疫性疾病患者提供一流的誘導多能幹細胞（iPSC）衍生細胞免疫療法的臨床階段生物製藥公司Fate Therapeutics, Inc.（“公司” 或 “Fate Therapeutics”）（納斯達克股票代碼：FATE）今天宣佈，該公司將在23日出席年度Needham虛擬醫療會議將於美國東部時間2024年4月10日星期三下午2點15分舉行。
A live webcast, if recorded, of each presentation can be accessed under "Events & Presentations" in the Investors section of the Company's website at www.fatetherapeutics.com. The archived webcast will be available on the Company's website shortly after the event.
每場演講的網絡直播（如果錄製）可以在公司網站的 “投資者” 部分的 “活動與演講” 下觀看 www.fatetherapeits.com。存檔的網絡直播將在活動結束後不久在公司網站上公佈。
About Fate Therapeutics, Inc.
關於 Fate Therapeutics, In
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company's pipeline includes iPSC-derived natural killer (NK) cell and T-cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.
Fate Therapeutics是一家臨床階段的生物製藥公司，致力於爲癌症和自身免疫性疾病患者提供一流的誘導多能幹細胞（iPSC）衍生細胞免疫療法。利用其專有的iPSC產品平台，該公司在創建多路工程iPSC產品線以及現成iPSC衍生細胞產品的製造和臨床開發方面確立了領導地位。該公司的產品線包括iPSC衍生的自然殺傷（NK）細胞和T細胞候選產品，這些候選產品經過選擇性設計，採用了新的細胞功能合成對照，旨在爲患者提供多種治療機制。Fate Therapeutics總部位於加利福尼亞州聖地亞哥。欲了解更多信息，請訪問 www.fatetherapeits.com。
Contact:
Christina Tartaglia
Stern Investor Relations, Inc.
212.362.1200
christina.tartaglia@sternir.com
聯繫人：
克里斯蒂娜·塔塔利亞
斯特恩投資者關係有限公司
212.362.1200
christina.tartaglia@sternir.com
Source: Fate Therapeutics, Inc.
來源：Fate Therapeutics, Inc.
譯文內容由第三人軟體翻譯。